Oral Teriflunomide significantly reduced MS relapse rates

Aubagio is an oral treatment approved for MS.

Oral Teriflunomide significantly reduced MS relapse rates

Postby MSUK » Mon Aug 30, 2010 1:31 am

Image

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial.

Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo.. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2088
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Aubagio (teriflunomide)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users